While improving, demand-side fundamentals in Greater Boston’s laboratory market remain challenged as life science users continue to exhibit cautiousness in their real estate decisions.
The free-flowing funding climate in biotech slowed to a trickle in 2022, choking off the supply of tenants to fill Boston’s explosion of new life science real estate.
Moves by the California-based Alexandria Real Estate Equities to dump a significant slice of its Boston-area life science real estate portfolio speak volumes about the state of the local lab market, none of it good.
